

**Shield Therapeutics plc**  
("Shield" or the "Company" or the "Group")

***Total Voting Rights***

**London, UK, 01 October, 2025:** Shield Therapeutics plc (LSE: STX), a commercial-stage pharmaceutical company specialising in iron deficiency confirms that in accordance with the requirements of the FCA's Disclosure and Transparency Rule 5.6.1, the Company's issued share capital consists of 1,061,802,812 ordinary shares of 1.5p each in issue, each with equal voting rights. No shares are held in treasury.

The above figure may also be used by shareholders as the denominator in the calculations by which they will determine whether they are required to notify their interest, or a change to their interest, in the Company under the FCA's Disclosure Guidance and Transparency Rules.

**For further information please contact:**

**Shield Therapeutics plc**

Anders Lundstrom, CEO  
Santosh Shanbhag, CFO  
Stephanie Hicks, Investor Relations

[www.shieldtherapeutics.com](http://www.shieldtherapeutics.com)

+44 (0) 191 511 8500

[Investorrelations@shieldtx.com](mailto:Investorrelations@shieldtx.com)

**Nominated Adviser and Joint Broker**

**Peel Hunt LLP**

James Steel

+44 (0)20 7418 8900

**Joint Broker**

**Cavendish Ltd**

Geoff Nash/ Isaac Hooper/Nigel Birks/Harriet Ward

+44 (0)20 7220 0500

**About Iron Deficiency and ACCRUFer®/FeRACCRU®**

Clinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a 2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, ACCRUFer® has the potential to meet an important unmet medical need for both physicians and patients and is now the leading **#1 branded prescription oral iron the market today** (data source - IQVIA Xponent PlanTrak).

ACCRUFer®/FeRACCRU® (ferric maltol) is a novel, stable, non-salt-based oral therapy for adults with ID/IDA. The drug has a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about ACCRUFer®/FeRACCRU®, including the product label, can be found at: [www.accrufer.com](http://www.accrufer.com) and [www.feraccru.com](http://www.feraccru.com).

**About Shield Therapeutics plc**

Shield is a commercial stage specialty pharmaceutical company that delivers ACCRUFer®/FeRACCRU® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched ACCRUFer® in the U.S. with an exclusive, multi-year collaboration agreement with Viatris. Outside of the U.S., the Company has licensed the rights to five specialty pharmaceutical companies. FeRACCRU® is commercialised in the UK and European Union by Norgine B.V., which also has marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of ACCRUFer®/FeRACCRU® in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea, with Kye Pharmaceuticals Inc. for Canada, and with VITAL-NET for Japan.

ACCRUFer®/FeRACCRU® has patent coverage until the mid-2030s.

ACCRUFer®/FeRACCRU® are registered trademarks of Shield Therapeutics.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

TVRWPURGBUPAGBU